5-Amino-2,4,6-triiodo-1,3-benzenedicarbonyl dichloride:Exports & Compliance White Paper 2026

I. Executive Summary

5-Amino-2,4,6-triiodo-1,3-benzenedicarbonyl dichloride (CAS 37441-29-5) is the triiodinated isophthaloyl dichloride core used to build non-ionic iodinated X-ray contrast media of the iohexol, iopamidol, iodixanol, ioversol and iopromide families. Its formula C8H2Cl2I3NO2 and molecular weight of about 595.7 g/mol reflect an iodine content near 64 percent by mass, which is the property that matters: iodine provides the X-ray attenuation. The substance is therefore not a general-purpose intermediate but a registered pharmaceutical building block, supplied under quality agreements to licensed contrast-media manufacturers and their qualified partners.

Commercially the molecule sits at the intersection of three pressures. Chemically it is an acid dichloride that liberates hydrogen chloride on contact with moisture and hydrolyses back to the diacid, so manufacturing, packaging and logistics must be engineered around dryness. Economically it carries roughly two-thirds of its mass as iodine, making the iodine market and recovery efficiency direct determinants of cost. Regulatorily it is a GMP-relevant intermediate subject to ICH Q7 and Q11, DMF or CEP support, elemental-impurity and residual-solvent control, and audit by the contrast-media manufacturers who answer to FDA, EMA and other agencies.

For buyers the decisive variables are completeness of the iodination pattern, since mono- and di-iodinated species are the critical related substances, free iodide and ionic-iodine limits, residual chlorinated solvents under ICH Q3C, moisture and acidity, thermal and hydrolytic stability in the delivered pack, and the supplier's audit and documentation record. Responsible suppliers restrict distribution to verified pharmaceutical manufacturers and documented research users, and they refuse orders that cannot be reconciled with legitimate contrast-media manufacture or analytical work.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The molecular design is deliberately overloaded: three heavy iodine atoms deliver radiopacity, the 5-amino substituent carries the side chains that make the final agent non-ionic and water-soluble, and the two acyl chloride functions provide the coupling chemistry to attach them or to dimerise two rings. Each feature also creates a failure mode, which is the basis of both process design and specification.

• Iodine Density and Radiopaque Function: Iodine's high atomic number gives strong photoelectric absorption in the diagnostic energy range, and placing three iodine atoms on each ring allows finished agents to reach the iodine concentrations required for vascular and CT imaging. This is why iodine mass fraction governs the economics of the intermediate, and why deiodination is the most consequential degradation pathway.
• Acyl Chloride Reactivity and Hydrolytic Instability: The acid chloride groups react rapidly with water, alcohols and amines, releasing hydrogen chloride and reverting to the carboxylic acid, so the material must be made, isolated, dried and packed under dry inert conditions. Thermal stress matters equally: elevated drying temperatures accelerate hydrolysis and deiodination, so drying is run under vacuum at controlled temperature with monitoring of acidity and free iodide.

2.2 Synthesis and Manufacturing Technologies

The industrial sequence is a two-stage transformation: exhaustive electrophilic iodination of an isophthalic acid derivative bearing the 5-amino substituent, followed by conversion of both carboxylic acids to acyl chlorides. Both stages are hazardous in different ways, iodination through corrosive electrophilic iodine species and heavy iodine inventories, acid-chloride formation through sulfur oxides, hydrogen chloride and carbon oxides. Equipment selection, abatement and containment define feasibility more than yield does.

• Regioselective Electrophilic Triiodination: Iodination is performed with iodine monochloride or with iodine generated in the presence of an oxidising system, exploiting activation by the amino group to drive substitution at the 2-, 4- and 6-positions. Control focuses on driving the reaction to the tri-iodo stage, since partially iodinated species co-crystallise and are difficult to purge, on quenching residual electrophilic iodine to iodide, and on recovering iodine from mother liquors and washes.
• Acyl Chloride Formation and Off-Gas Management: Conversion uses thionyl chloride or oxalyl chloride, often with catalytic amide activation, in glass-lined or high-alloy equipment under dry inert atmosphere. The process generates hydrogen chloride and sulfur dioxide or carbon oxides, requiring multi-stage absorption and scrubbing with monitoring, while isolation must control residual reagent, acidity and chlorinated solvent to ICH Q3C limits before drying and packing.

2.3 Core Application Matrix

• Non-Ionic Iodinated Contrast Media Manufacture: The principal use is as the iodinated aromatic core for non-ionic agents, where the acyl chloride functions are coupled with hydroxyalkyl amide side chains to give the hydrophilic, low-osmolality finished substances. Supply into this application is restricted to licensed pharmaceutical manufacturers and operates under GMP, DMF or CEP support and long-term quality agreements.
• Dimeric and Ionic Agent Process Development: Development programmes use the intermediate to explore dimeric structures and alternative side-chain architectures, where two triiodinated rings are linked to raise iodine delivery per molecule. Work at this stage is process research and analytical development, not clinical use, and is supported by flexible kilo-lab and pilot campaigns.
• Analytical Standards and Related-Substance Work: The compound and its deiodinated, hydrolysed and partially substituted relatives serve as reference materials for related-substance methods, free-iodide determination and stability-indicating assays in contrast-media quality control. Buyers here require certified identity, stated purity basis and documentation suitable for regulated laboratory use.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand derives from diagnostic imaging volumes: CT and angiographic procedures, ageing populations and expanding interventional cardiology and oncology imaging. Because contrast-media manufacturing is concentrated, disruption at a single plant propagates quickly; the shortage experience earlier in this decade, triggered by lockdown at a major contrast-media plant in China, showed how little buffer exists between intermediate supply and hospital schedules. That pushed manufacturers to qualify second sources and hold more inventory.

3.2 Capacity Distribution and Export Flows

Qualified capacity is limited and concentrated. Integrated contrast-media manufacturers in Europe, together with Japanese producers, operate much of the captive iodination and acid-chloride capability; Chinese producers in Zhejiang, Jiangsu and Shandong supply both domestic contrast-media API manufacture and export intermediate; Indian contractors in Hyderabad and Gujarat serve as qualified second sources with DMF support. Flows follow the finished-agent plants rather than open trading, with material moving under quality agreements and often on annual contracts.

3.3 Market Bifurcation and Pricing Dynamics

Pricing is best understood as iodine cost plus conversion plus compliance premium. Iodine is a concentrated, price-volatile mineral commodity, so contracts commonly carry iodine price adjustment clauses and recovery credits. The GMP and audit premium is substantial and persistent, because qualifying an alternative iodination and acid-chloride source requires regulatory variation for the finished agent. Buyers therefore optimise for security of supply and documentation continuity, not spot price.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Compliance for this intermediate runs on two tracks that must be reconciled. The chemical track covers REACH registration, CLP classification and TSCA status for the substance itself. The pharmaceutical track covers ICH Q7 GMP for the intermediate, ICH Q11 development documentation, ICH Q3C residual solvents, ICH Q3D elemental impurities, DMF or CEP support and inspection readiness. Supply is restricted to licensed pharmaceutical manufacturers and documented research users, with written end-use declarations.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH Registration and Dossier Stewardship: Manufacturers and importers must hold or rely on a registration covering the tonnage band, with a dossier that addresses the hydrolytic behaviour of the substance and the properties of its hydrolysis products, and must keep exposure scenarios aligned with actual handling in closed, dry systems. Because the substance is a registered pharmaceutical intermediate, changes in supplier or process trigger reassessment by downstream marketing-authorisation holders.
• CLP Classification and GMP Expectations: Classification must reflect corrosivity from hydrogen chloride liberation, acute toxicity and aquatic hazard, and the label, safety data sheet and transport documentation must be mutually consistent. For GMP supply, European inspectors apply EU GMP Part II, which mirrors ICH Q7, and expect validated cleaning, control of the acid-chloride stage, documented impurity fate and purge, and full traceability of iodine and solvent inputs.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA Status and EPA Obligations: Importers must confirm TSCA inventory status and assess chemical data reporting and significant-new-use obligations, while site-level environmental permitting covers hydrogen chloride and sulfur dioxide emissions from the acid-chloride stage. Facilities handling electrophilic iodine species also manage occupational exposure through closed charging, local exhaust and monitoring, with hydrogen chloride detection in process areas.
• FDA GMP, DMF and ICH Control: Contrast-media manufacturers file and maintain drug master applications referencing this intermediate, so suppliers must support the filing with open or closed DMF content, change control, impurity qualification and stability data. Expectations include ICH Q7 GMP, ICH Q11 development rationale, ICH Q3C solvent limits and ICH Q3D elemental-impurity assessment for catalysts and metal surfaces, with audit rights exercised by the finished-product manufacturer.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

ESG performance for iodinated intermediates is inseparable from the iodine cycle and from acid-gas abatement. Buyers' questionnaires increasingly require ISO 14001 certification, abatement efficiencies for hydrogen chloride and sulfur dioxide, iodine-recovery rates and solvent-recovery data, and pharmaceutical customers extend these requirements through supplier qualification and audit.

5.1 Carbon Footprint and Circular Economy

The dominant burdens are iodine production upstream, chlorinated-solvent use, energy for vacuum drying and abatement, and cold dry logistics. Iodine recovery is the most valuable circular-economy lever: recovering iodide from mother liquors and washes, converting it back to elemental iodine or to an electrophilic iodinating reagent, reduces both cost and upstream footprint. Chlorinated-solvent recovery by distillation, and energy integration around drying, deliver the next largest gains, while Scope 3 data remain immature.

5.2 Sustainable Sourcing and Traceability

Traceability must cover the origin of iodine, since production is geographically concentrated and supply disruptions have historically moved prices sharply, the lot genealogy of the aromatic precursor, acid-chloride reagent supply, subcontracted steps and the raw data behind free-iodide and related-substance results. Pharmaceutical customers require documented chain of custody, audit rights and change control, and increasingly ask about iodine sourcing resilience as a business-continuity question.

VI. Supply Chain Resilience and Export Logistics

Logistics risk is dominated by moisture ingress, which hydrolyses the product and generates hydrogen chloride in a closed container, and by thermal exposure, which accelerates deiodination. Because qualifying an alternative source requires regulatory work downstream, resilience is built through inventory, dual qualification and packaging integrity rather than through spot-market flexibility.

6.1 Packaging Standards and Moisture/Contamination Control

• Sealed, Dry and Inert Inner Containment: Product should be filled hot-free and dry into moisture-barrier containers sealed under dry nitrogen with desiccant, using corrosion-compatible liners and closures, then outer-packed rigidly. Every filling operation must be qualified for residual moisture and headspace dryness, since even small water ingress converts acyl chloride to acid and generates hydrogen chloride pressure in the pack.
• Cold Dry Chain and Damage Containment: Shipments move under controlled, cool conditions with humidity and temperature logging, segregated from aqueous and alkaline goods, and with clear instructions that any damaged pack must be treated as an acid-gas hazard. Warehousing should be dry and temperature-controlled, with stock rotation and retest intervals justified by stability data generated in the commercial pack.

6.2 Dangerous Goods Identification and Transit Protocols

Classification must be established from data or defensible read-across before first shipment; acyl chlorides liberating hydrogen chloride on contact with water are generally assessed as Class 8 corrosive solids and consigned under the relevant corrosive-solid UN entry with the applicable packing group and ADR, IMDG or IATA instruction. Sea freight should be booked away from heat sources and incompatible cargo with humidity logging, while air shipments require dangerous-goods acceptance and pre-cleared documentation to avoid demurrage.

VII. Enterprise Global Expansion Strategy Guide

Entry into this market is slow and documentation-led: qualification cycles are long, switching costs for the finished-agent manufacturer are regulatory, and trust is built through audits. The priorities below reflect how contrast-media supply organisations actually select and retain intermediate partners.

1. Master the Iodine Cycle: Invest in iodide recovery from liquors, conversion back to electrophilic iodinating reagent, iodine inventory hedging and mass-balance accounting that documents recovery rates. Iodine efficiency is simultaneously the largest cost lever, the strongest ESG argument and the clearest defence against raw-material price shocks.
2. Build GMP, DMF and Audit Readiness: Operate to ICH Q7 with ICH Q11 development documentation, maintain DMF or CEP support packages, validate cleaning for the acid-chloride stage, and document impurity fate and purge with ICH Q3C and Q3D alignment. Audit readiness, change control and data integrity determine whether qualification succeeds.
3. Institutionalise Restricted Distribution: Apply Know-Your-Customer verification, written end-use declarations and documented refusal of orders that cannot be reconciled with licensed contrast-media manufacture or analytical work. Pair this with dual-qualified manufacturing sites and iodine sourcing options so customers can rely on continuity.

VIII. Conclusion

5-Amino-2,4,6-triiodo-1,3-benzenedicarbonyl dichloride is a strategically sensitive pharmaceutical intermediate whose value is defined by iodine content, dryness and documentation. Its market rewards suppliers who can run corrosive electrophilic iodination and acid-chloride chemistry safely, recover iodine efficiently, exclude moisture from manufacture through to delivery, and support the finished-agent manufacturer's regulatory filings without interruption.

Because the diagnostic imaging supply chain has little buffer, resilience is now a purchasing criterion alongside price: buyers qualify second sources, hold intermediate inventory and contract on iodine-adjusted terms. Suppliers who combine GMP credibility, abatement and recovery performance, restricted-distribution discipline and cold dry logistics will remain preferred partners; those who treat the substance as a generic acid chloride will not pass qualification.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global 5-Amino-2,4,6-triiodo-1,3-benzenedicarbonyl dichloride Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global 5-Amino-2,4,6-triiodo-1,3-benzenedicarbonyl dichloride supply chain:

• China Iodination and Contrast-Media Intermediate Base: Producers in Zhejiang, Jiangsu and Shandong combine electrophilic iodination with acid-chloride capability and, increasingly, domestic contrast-media API manufacture, offering scale and cost advantages. Strengths are capacity, iodine sourcing relationships and integration; buyers should verify GMP status, abatement performance, free-iodide control and DMF support before qualification.
• India DMF-Supported CDMO Cluster: Contractors in Hyderabad, Gujarat and Maharashtra supply iodinated intermediates with DMF documentation, ICH-aligned impurity and solvent control, and established audit experience with regulated customers. They are the most common second-source choice for contrast-media manufacturers seeking to reduce single-site dependency.
• Europe and Japan Incumbent Contrast-Media Corridor: Western European contrast-media manufacturers operate captive or tightly partnered iodination capability under full GMP, while Japanese groups bring deep expertise in iodine chemistry and stable access to iodine supply. This corridor sets the quality and documentation benchmark and is the destination for much of the exported intermediate volume.